A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
Mairead Geraldine McNamara
No relevant relationships to disclose
Anne M Horgan
No relevant relationships to disclose
Alex Aspinall
No relevant relationships to disclose
Eric Xueyu Chen
No relevant relationships to disclose
Kelly Burak
No relevant relationships to disclose
Neesha C. Dhani
No relevant relationships to disclose
Jennifer Petronis
No relevant relationships to disclose
Mehrdad Sinaei
No relevant relationships to disclose
Tae Kyoung Kim
No relevant relationships to disclose
Patrik Rogalla
No relevant relationships to disclose
Oliver F. Bathe
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose